A Phase 1/2a Multi-Center, Dose-Escalation Study to Evaluate the Safety & Efficacy of Eyecyte-RPE™ When Administered as a Single-dose Subretinal Injection in Subjects With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
Latest Information Update: 18 Apr 2025
At a glance
- Drugs Eyecyte-RPE (Primary)
- Indications Dry age-related macular degeneration
- Focus First in man; Therapeutic Use
- Sponsors Eyestem
- 15 Apr 2025 According to a Eyestem media release, the company will be presenting its data at the ARVO 2025 Annual Meeting as well as the 10th Retinal Cell and Gene Therapy Innovation Summit in early May.
- 15 Apr 2025 Results presented in the Eyestem media release.
- 06 Jan 2025 According to a Eyestem media release, the company Completing the first three patient injections of Eyecyte-RPE™ represent a critical milestone for our quest to find a cure for Dry AMD.